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Activated estrogen receptor (ER) plays a critical role in breast cancer development and is a
major target for drug treatment. Serine phosphorylation within the N-terminal domain (NTD)
contributes to ER activation and may also cause drug resistance. Previous biochemical
identification of phosphorylated ER residues was limited to protein artificially overexpressed
in transfected cell lines. We report mass spectrometric methods that have allowed the
identification of a new site within the NTD of ER isolated from cultured human breast cancer
cells. Immunoprecipitation, trypsin digestion, and analysis by nano-LC-ESI-MS/MS (Q-STAR,
MDS Sciex) and vMALDI-MSn (Finnigan™ LTQ™, Thermo-Electron) identified peptides
containing 8 of 14 serine residues within the NTD, one being partially phosphorylated Ser-167,
known but not previously reported by MS. Chymotrypsin digestion revealed other known
sites at Ser-102/104/106 and 118. Tandem methods developed for the peptide containing
Ser-118 and the use of hypothesis-driven experiments—i.e., the assumption that an intact
phosphopeptide showing no molecular ion might yield fragment ions including loss of
phosphoric acid in vMALDI-MS/MS—allowed the identification of a novel site at Ser-154.
Quantitation by selected reaction monitoring demonstrated 6-fold and 2.5-fold increases in
Ser-154 phosphorylation in estradiol- and EGF-treated cells, respectively, compared to
controls, confirmed by immunoblotting with a novel rabbit polyclonal antibody. Thus, the
protein isolation and MS strategies described here can facilitate discovery of novel phosphor-
ylation sites within low abundance, clinically important cancer targets like ER, and may
thereby contribute to our understanding of the role of phosphorylation in the development of
breast cancer. (J Am Soc Mass Spectrom 2008, 19, 729–740) © 2008 American Society for Mass
SpectrometryEstrogen receptor alpha (ER) belongs to the su-perfamily of nuclear receptors displaying a char-acteristic modular domain structure (Figure 1)
consisting of N-terminal domain (NTD), DNA binding,
hinge and C-terminal ligand binding domains [1–3]. Of
ER’s two distinct, non-acidic activation function do-
mains (AF-1, AF-2), the C-terminal AF-2 domain is
highly conserved among species and other nuclear
hormone receptors and becomes activated only in re-
sponse to ligand binding, whereas the N-terminal AF-1
domain is less well conserved [2–6] and displays an
unfolded structure yet becomes activated in response to
both ligand-dependent and -independent mechanisms
[1, 7]. The distribution and site occupancy of post-
translational modifications (PTMs), particularly serine
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doi:10.1016/j.jasms.2008.02.008phosphorylation, are emerging as important indicators
of ER functional status [2]. With five (Ser-102, Ser-104,
Ser-106, Ser-118, Ser-167) of the NTD’s 14 serine resi-
dues known to be targets of phosphorylation determin-
ing recruitment of various ER cofactors, this domain
clearly coordinates many aspects of ER activation [2, 3,
7–10]. In vitro and clinical studies also suggest that
molecular cross talk involving various growth-factor
signaling pathways, particularly those leading to phos-
phorylation of ER-NTD, contribute to de novo and
acquired endocrine resistance, a major problem in
breast cancer treatment [2, 8, 11–21].
A number of groups have reported a major role for
Ser-118 phosphorylation in the ligand-induced activa-
tion of ER, given that mutation of this serine to alanine
results in a diminished transcriptional response to es-
tradiol activation compared with wild-type ER [7].
Also, ligand-induced phosphorylation of Ser-167, al-
though initially a contested issue, is now clearly recog-
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ER-NTD and ER DNA-binding [2, 22–25]. In the
context of ligand-independent ER stimulation, as with
EGF growth induction under serum deprivation, both
of the aforementioned NTD serine residues become
phosphorylated [7]. However, although many of the
candidate kinases directing phosphorylation of NTD
serine residues have been described, it is still unknown
what constellation of phosphorylated serine residues
determines the various activated states of ER.
To date, no phosphorylation of endogenous ER has
been reported to be observed by mass spectrometry.
Nevertheless, in keeping with suspicions that critical
serine phosphorylation sites within ER-NTD might
remain undetected [26, 27], the present study interro-
gated the phosphorylation status of endogenous ER-
NTD using mass spectrometry (MS) and tandem MS
(MS/MS) after estradiol (E2) or growth factor (EGF)
stimulation of ER-positive human breast cancer cells
(MCF-7). MS procedures have become an increasingly
important analytical means of detecting phosphory-
lated serine/threonine and tyrosine residues [28, 29]
due to the high level of sensitivity and unbiased ability
of MS to scan proteolytic digests for various PTMs; and
of particular utility given focus on the ER-NTD was
the hypothesis-driven multi-stage mass spectrometric
approach described by Chang et al. [30]. Earlier studies
also pointed to the advantages of using different MS
platforms to optimize protein coverage and peptide
fragment sensitivity, since proteolytic peptides can ex-
hibit differential responses to alternative ionization
conditions, exemplified by the use of both ESI-MS/MS
and vacuum (v)MALDI-MSn platforms to confirm
known and identify new phosphorylation sites within
the key protein (huntingtin) involved in Huntington’s
disease [31]. In the present MS study of endogenous
ER extracted and purified from ligand-dependent (E2)
Figure 1. (a) The domain structure of ER, inc
containing AF-1 (NTD/AF-1), the DNA-bindin
containing AF-2 (LBD/AF-2). (b) Detail of the N
within the NTD. Phosphorylation has been repo
106, 118, and 167). Residue 154 (shown in blue)
site.versus ligand-independent (EGF) stimulated humanbreast cancer cells, we sought to avoid potential arti-
facts associated with analysis of recombinant synthetic
protein or ectopically overexpressed intracellular ER,
but this was reliant on the development of efficient and
MS-compatible immunocapture and ER purification
steps that would be insensitive to the presence or
absence of possible PTMs, particularly phosphoryla-
tion. Furthermore, because we sought to carry out
relative quantitative measurements it was essential to
preserve the ratios of modified to unmodified peptides
that would be representative of any phosphorylation
within the original protein. A phospho-enrichment pro-
cedure would negate this and would likely result in
differential enrichment of the various phosphorylated
species; therefore we avoided using enrichment proce-
dures such as IMAC (immobilized metal-ion affinity
chromatography) [32–35], strong cation exchange [36,
37], or phospho-specific immunoprecipitation [38]. Us-
ing an optimized MS approach developed by monitor-
ing known phosphorylation sites, Ser-118 and Ser-167,
we demonstrated that Ser-154 in ER-NTD, long sus-
pected but unconfirmed as being phosphorylated under
endogenous intracellular conditions [27], is indeed par-
tially phosphorylated under both ligand-dependent
and ligand-independent human breast cancer growth
conditions.
Experimental
Materials
2-Methylnaphthalene-1,4-dione (Menadione), 17--estradiol,
dithiothreitol (DTT), iodoacetamide (IAA), formic acid
(FA), and trifluoroacetic acid (TFA) were purchased
from Sigma–Aldrich (St. Louis, MO, USA). The recom-
binant  isoform of ER (66.2 kDa) was obtained from
Pan Vera (Madison, WI, USA). Agarose conjugated
g the largely unstructured N-terminal domain
main (DBD), and the ligand binding domain
of ER. Arrows indicate the 14 serine residues
for the 5 serine residues shown in red (102, 104,
entified here as a novel serine phosphorylationludin
g do
TD
rted
is id(sc8002AC) and free anti-ER F10 antibodies (sc8002)
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Cruz, CA, USA). Phospho-S104/106, phospho-SER-118,
and phospho-SER-167 antibodies were purchased from
Cell Signaling Technology (Danvers, MA, USA).
Sequencing-grade modified porcine trypsin was from
Promega (Madison, WI, USA) and sequencing-grade
modified bovine chymotrypsin was from Princeton Sepa-
rations (Adelphia, NJ, USA). HPLC solvents, acetonitrile
(ACN), and water were obtained from Honeywell Bur-
dick and Jackson (Muskegon, MI, USA), 2,5-dihydroxy-
benzoic acid (DHB) from LaserBio Labs (Sophia Antipolis,
France), and -cyano-4-hydroxycinnamic acid (CHCA)
from Agilent Technologies (Santa Clara, CA, USA).
Cell Culture
Recombinant ER was used to quantitate the yield of
protein derived from the immunoprecipitation (IP) step
and to optimize digestion and peptide analysis by MS
but all the data presented here were obtained on ER
extracted from the MCF-7 human breast cancer cell line.
This was obtained from the American Type Culture
Collection (Manassas, VA, USA) and maintained in
Dulbecco’s modified Eagle’s medium (Mediatech,
Herndon, VA, USA) supplemented with 10% fetal bo-
vine serum (Mediatech), 1% penicillin/streptomycin
(Mediatech), and 10 g/ml insulin (Sigma). Treatment
conditions for all cell lines involved plating approxi-
mately 3  106 cells in normal media onto 15-cm dishes
and attachment and growth for 24 h. Before estradiol
(E2) treatment (10 nM, 30 min), cells were grown in
estrogen-free culture conditions (phenol red-free Dul-
becco’s modified Eagle’s medium-H-16 supplemented
with 10% charcoal-stripped serum, 1% penicillin/strep-
tomycin, and 10 g/ml insulin) for 24 h to eliminate
any artifactual estrogen stimulatory influences or estro-
gen metabolism to catechols and quinones. Before EGF
treatment (50 ng/ml, 10 min) cells were grown in
serum-free conditions for 24 h to eliminate any artifac-
tual growth factor influences present in the fetal calf
serum.
IP, SDS-PAGE, and In-Gel Proteolytic Digestion
After aspiration of culture media and one room-
temperature phosphate-buffered saline (PBS) wash,
cells from 20  15-cm plates were harvested on ice
using a cell scraper and 0.8 mL of ice-cold cell lysis
buffer [100 mM NaCl, 20 mM Tris (pH 7.5), 0.5%
IGEPAL, 100 mM NaF, 10 mM Na3VO4, 50 mM
Na2MoO4, 10 L/mL phosphatase inhibitor cocktail I
(Sigma–Aldrich), 320 nM Okadaic acid, 100 U/mL
deoxyribonuclease I and 1 tablet/10 mL Roche mini-
complete protease inhibitor cocktail]. Cellular con-
tents were transferred to 1.5-mL Eppendorf tubes,
sonicated (10 s) twice per tube, then centrifuged at
16,000 rpm (30 min, 4 °C) and collected into one
50-mL universal tube (25 mL total). Agarose-conju-
gated F-10 ER antibody (160 L, prewashed in 0.5%IGEPAL/PBS buffer) was added to the cell lysate and
allowed to incubate by gently rotating in a cold room
overnight. The immune complex was centrifuged at
1000 rpm at 4 °C for 1 min, supernatant removed, and
the complex transferred to a 1.5-mL Eppendorf tube
and washed with a PBS-based buffer (PBS, 0.5%
IGEPAL) for 10 min at room temperature. The wash,
centrifugation, and elution of supernatant were re-
peated three more times and the resultant pellet was
re-suspended in 20 L 4 protein elution buffer [100
mM NaCl, 4% (wt/vol) SDS, 25 mM Tris (pH 7.5)].
Samples were heated to 92 °C for 7 min then the
elution buffer was removed from the beads using a
gel-loading tip and stored in a separate Eppendorf
tube. The heating, removal, and storage of elution
buffer were repeated twice, first after adding 15 L of
4 elution buffer and, second, after adding 10 L of
4 elution loading buffer. A razor blade was used to
remove the tip of the Eppendorf tube (containing the
Ab-beads and inaccessible elution buffer) placed into
a 100 MW Microcon (Millipore, Bedford, MA, USA)
centrifugal filter device (tip pointing up) and centri-
fuged at 11,000 g for 5 min to remove all remaining
elution buffer and proteins from the Ab-beads. This
too was added to the separate Eppendorf tube con-
taining the previously eluted proteins (55 L final
volume). Loading buffer [10 L; 100 mM NaCl, 25
mM Tris (pH 7.5), 30% glycerol, 0.5% IGEPAL, 4%
SDS, bromophenol blue] was added to the eluted
protein solution and heated at 92 °C for a further 5
min. All 65 L of sample was added to one well on a
1.5-mm-thick 10-well Nu-PAGE 4 to 12% Bis-Tris gel
(Invitrogen, Carlsbad, CA, USA). After electrophore-
sis, gels were stained with the Imperial protein dye
(Pierce, IL, USA), then destained in water. Bands at 66
kDa (ER) were excised, chopped, destained, and
dehydrated with ACN. Proteins were subsequently
reduced with 10 mM dithiothreitol in 25 mM
NH4HCO3 at 56 °C for 1 h and alkylated with 55 mM
iodoacetamide in 25 mM NH4HCO3 at room temper-
ature for 45 min. Samples were then washed, dried,
rehydrated on ice for 10 min in 125 ng of sequence-
grade trypsin or 200 ng chymotrypsin, reconstituted
in 25 mM NH4HCO3, covered with an additional 20
L NH4HCO3 solution, and incubated overnight,
either at 37 °C or room temperature, respectively. The
resulting proteolytic peptides were subjected to aque-
ous (30 L NH4HCO3, 20 min vortex) and hydropho-
bic extraction (2  30 L of 50% ACN, 5% formic acid,
20 min vortex, 10 min sonication), concentrated under
vacuum to 20 L, and stored at 80 °C until used for
mass spectrometry.
Mass Spectrometry
Unseparated proteolytic peptide mixtures were ana-
lyzed by MALDI-TOF-MS on a Voyager DESTR Plus
instrument (Applied Biosystems, Foster City, CA,
USA). The peptide mass fingerprints confirmed the
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extracted from the MCF-7 cells by IP. The latter samples
were further analyzed by reverse-phase nano-HPLC-
MS/MS using an Ultimate HPLC (Dionex, Sunnyvale,
CA, USA) with the C18 analytical column directly
connected to a Q-STAR Pulsar I quadrupole orthogonal
TOF mass spectrometer (MDS Sciex, Concorde, Can-
ada) as previously described [31]. In addition, unsepa-
rated peptide mixtures were analyzed by MALDI-MS,
MS/MS, MS3, and MS4 on a vMALDI-LTQ™ linear ion
trap (Thermo Fisher, San Jose, CA, USA) with 2,5-
dihydroxybenzoic acid (DHB; LaserBio Labs) in 10%
ACN/0.5% TFA as matrix. All ions observed in the
vMALDI-MS spectrum were subjected to MS/MS to
probe for the neutral loss of phosphoric acid (98 Da)
[30]. Species that showed this loss were interrogated
further by MS3 by selecting the (M  H  98) peak as
precursor ion. For the hypothesis-driven investigation,
all ER-NTD peptides observed to contain unmodified
serine residues were interrogated for possible phos-
phorylation by carrying out MS/MS at a mass 80 m/z
units greater than the observed molecular ion, irrespec-
tive of whether any ions could be observed at this mass
[28, 29].
For relative quantitation, vMALDI-LTQ in selected
reaction monitoring (SRM) mode was used to monitor the
levels of Ser-154 phosphorylation in the peptide corre-
sponding to residues 143–158 (EAGPPAFYRPNSDNRR)
between different treatment samples, compared with the
untreated control sample. A method was developed to
carry out three scan events: (1) an MS scan (1000–2000
m/z), (2) an SRM MS/MS scan at 1927.00 m/z (1.5 m/z)
monitoring 1215.0–1221.0 m/z to measure the intensity
of the c11 fragment ion (1217.6 m/z) from the phosphor-
ylated peptide, and (3) an SRM MS/MS scan at 1847.00
m/z (1.5 m/z), again monitoring 1215.0–1221.0 m/z to
measure the intensity of the same c11 fragment ion from
the corresponding unmodified peptide. This trio of scan
events was carried out 30 times for each sample spot
and repeated 4 times for each treatment sample. There
were two biological repeats. The unmodified to phos-
phorylated c11 ion intensity ratio was then used to
represent the level of Ser-154 phosphorylation in each
treatment sample as a fold induction relative to the
untreated control sample. The following formula was
used to calculate any treatment induced increase in
Ser-154 phosphorylation from the vMALDI data:
C11 PEstradiol
C11 non-PEstradiol
C11 PControl
C11 non-PControl
Bioinformatics and Protein Database Searches
MALDI-TOF-MS data were analyzed using Data Ex-
plorer 4.0™ (Applied Biosystems) and peptide mass
fingerprints were searched against the Swiss-Prot mam-malian database using Mascot (Matrix Sciences, Lon-
don, UK). For ESI-MS/MS datasets, tandem mass spec-
tra were submitted to our Mascot in-house database
search engine (version 2.1) [39]. vMALDI-MSn data
were analyzed using Xcalibur 2.0 SR2 software and
database searches to identify phosphopeptides were
performed using Bioworks software version 3.2 (Turbo
SEQUEST search engine) allowing for mass accuracies
of 2 Da (for vMALDI-MS precursor ions) and 1 Da (for
vMALDI-MSn fragment ions) [40]. For the QSTAR LC-
MS/MS datasets, three-dimensional images of the total
ion chromatogram were generated using MSight 1.0
(Swiss Institute of Bioinformatics, http://www.expasy.
org/MSight/).
Phospho-Ser-154 Antibody Production
A 14 amino acid peptide containing phosphorylated Ser-
154 with an N-terminal cysteine residue added for KLH
coupling was used to immunize two rabbits (Anaspec,
San Jose, CA, USA). Following boostings with ELISA
assays confirming antibodies specific for the phospho-
Ser-154 peptide relative to the non-phosphorylated
peptide, serum from both rabbits was affinity puri-
fied on a phospho-Ser-154 peptide column. Antibod-
ies eluting from the phospho-Ser-154 column were
reselected using a non-phosphorylated Ser-154 pep-
tide column with the flow through fraction constitut-
ing the phospho-Ser-154 antibody pool used for
Western analysis.
Results and Discussion
Phosphorylation Status of ER Purified from
MCF-7 Human Breast Cancer Cells
Because the protocol used to isolate ER from MCF-7
whole cell lysates involved 12 h of immunopurification
using an agarose-coupled ER antibody, it was essen-
tial to ensure complete inactivation of endogenous
phosphatases (see Experimental section) and full pres-
ervation of ER phosphorylation status. Using commer-
cially available antibodies to detect phosphorylated
ER serine residues, including phospho-Ser-104/106,
phospho-Ser-118, and phospho-Ser-167, aliquots of the
immunopurified ER from E2-treated, control E2 (char-
coal-stripped serum, phenol red-free media), EGF-
treated, and control EGF (phenol red-free media)
MCF-7 cells were analyzed on Western blots. As shown
in Figure 2a, the phosphorylation status of the immu-
nopurified ER recapitulated known results [2, 7, 24],
with Ser-118 exhibiting the greatest phosphorylation in
response to E2, although still robustly phosphorylated
following EGF treatment, in which Ser-167 was the
dominantly phosphorylated serine in response to EGF,
although still significantly phosphorylated in response
to E2, and in which Ser-104/106 showed the greatest
phosphorylation with E2 treatment while becoming less
phosphorylated with EGF treatment.
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ylation following its immunopurification, large-scale iso-
lation of ER for MS analysis was performed using
approximately 108 human breast cancer MCF-7 cells per
treatment condition. Using commercially available recom-
binant human ER (rER) as a standard, the immunopre-
cipitated ER was subjected to one-dimensional SDS gel
electrophoresis. As shown in Figure 2b, following gel
staining, a clear protein band at 66 kDawas apparent from
the immunoprecipitated ER preparation, whosemobility
was consistent with the rER band. Based on the relative
intensity of this band derived from 6 pmol rER, it was
Figure 2. (a) Phospho-ER. Western analysis of total and phos-
phorylated ER at serine residues 104/106, 118, and 167 following
immunoprecipitation from MCF-7 cells treated with E2 (10 nM),
EGF (50 ng/mL), or appropriate control. (b) Immunoprecipitation
and one-dimensional SDS-PAGE. Coomassie-stained ER immu-
noprecipitated from MCF-7 cellular lysates using the agarose
conjugated anti-ER antibody (F-10), versus commercially ob-
tained recombinant ER (rER). (c) Western blot analysis; 10 L
aliquots from the same MCF-7 cell lysate before and after immu-
noprecipitation, probed with the F-10 antibody.estimated that approximately 6–10 pmol of ER wasextracted from 108 MCF-7 cells, which is consistent with
the estimated MCF-7 content of about 80 fmol ER/106
unstimulated cells. Additionally, Western analysis (Figure
2c) and densitometry of the cell lysate before and after
ER immunoprecipitation demonstrated that the ER
immunocapture procedure was roughly 95% efficient.
E2-Induced Phosphorylation of Ser-167
The region of the ER-NTD spanning residues 121–174
was previously suspected to contain unidentified phos-
phorylated serine residues [26, 27]. This was predicted
to yield informative peptides upon separate tryptic and
chymotryptic digestion that would be optimal for MS
analysis. Following proteolysis of the immunocaptured
ER band purified from E2-treated MCF-7 cells, the
resulting peptides were separated by on-line nano-
HPLC reversed-phase C18 chromatography and ana-
lyzed by a hybrid quadrupole time-of-flight mass spec-
trometer (Q-STAR). Selected peptide ions were
fragmented by collision-induced dissociation (CID) to
obtain peptide sequence information. The ESI-MS/MS
spectra were searched with Mascot (Matrix Science, Bos-
ton, MA, USA) using a custom-designed ER database.
Trypsin digestion resulted in the detection of peptides
covering 8 of the 14 ER-NTD serine residues in unmod-
ified form (Ser-10, 46, 47, 137, 154, 167, 173, and 178). In
addition, we were able to detect partial phosphorylation
of the known ER-NTD phosphorylation site Ser-167, the
phosphopeptide giving a Mascot score of 50, validated by
manual inspection and assignment of the fragment ions.
Figure 3a shows the ESI-MS/MS spectrum of the triply
protonated precursor ion [M  3H]3 at m/z 584.9 (M 
1751.7) of the mono-phosphorylated tryptic peptide
LApS167TNDKGSM*AM*ESAK, residues 165–180, with
M* corresponding to mono-oxidized methionine (i.e.,16
Da per modified residue). This CID spectrum is consis-
tent with the presence of a phosphate group at Ser-167.
Fragment ions corresponding to y- and b-ions were
observed, including several featuring the loss of 98 Da,
i.e., y1598 and y1498, attributable to the elimination
of a neutral phosphoric acid moiety (represented as
P). Significantly, MS/MS analysis of this mono-phos-
phorylated peptide produced no evidence for phos-
phorylation of the two other serine residues situated
within this peptide fragment, Ser-173 or Ser-178. Al-
though the fragmentation pattern did not discount
threonine-168 as a phosphorylated residue on this pep-
tide, the Western blotting data using the phospho-Ser-
167 antibody and previous studies provide unequivocal
evidence that the phosphorylated residue on this pro-
teolytic peptide is Ser-167.
Three-dimensional plots illustrated in Figure 3b
compare MS data for the Ser-167 phosphopeptide from
cells grown in the absence (control) or presence of E2.
The plots were generated using MSight 1.0, which
displays the Q-STAR total ion chromatogram with m/z,
chromatographic retention time, and ion intensity plot-
ted on the x, y, and z axes, respectively. When normal-
to u
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this demonstrates an approximate 8:1 increase in Ser-
167 phosphorylation relative to control, consistent with
the previous Western blots, thus corroborating the
immuno-affinity results in Figure 2. All other peaks
remain approximately the same intensity.
Chymotrypsin Digestion Revealed Other Known
Phosphorylation Sites
A substantial section of the NTD is devoid of basic
residues and is therefore resistant to trypsin digestion.
Chymotrypsin was used in an alternative digestion
Figure 3. (a) ESI-MS/MS spectrum of
LApS167TNDKGSM*AM*ESAK (residues 165–18
ER isolated from MCF-7 cells treated with
dimensional plots of ESI-MS representing m/z, re
respectively, showing increased ion current for
min, from cells treated with estradiol comparedscheme to probe the phosphorylation status of other serineresidues not seen in the tryptic digest. These include
Ser-102/104/106 and 118, previously identified as being
phosphorylated, although not reported bymass spectrom-
etry. Analysis of the unseparated peptide mixture derived
from chymotryptic digestion of the 66-kDa band again
confirmed the identity of ER from the MCF-7 cells. To
validate our method of detection of protein phosphoryla-
tion, the known phosphorylation site, Ser-118, was probed
using an adaptation of the hypothesis-driven multiple
stage mass spectrometric approach used by Chang et al.
[30]. Briefly, a 3-Da window was selected for vMALDI-
MS/MS at 80 m/z higher than the unmodified Ser-118–
containing peptide for the presence (or absence) of phos-
ly charged monophosphorylated peptide
/z 584.9 (M 1751.72) from tryptic digestion of
M*  mono-oxidized methionine.) (b) three-
n time, and ion intensity on the x, y, and z axes,
phorylated peptide m/z  584.9, eluting at 13.5
ntreated control.trip
0) atm
E2 (
tentio
phospho-Ser-118, based on the preferential neutral loss of
dehyd
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carried out on the corresponding (MHP) peak to pro-
vide sequence data to confirm or reject the presence of the
phosphorylated residue. Figure 4a shows the vMALDI-
MS/MS spectrum of peptide M*LLHPPPQLpS118PF (* 
methionine sulfoxide). When searched with Sequest using
the Bioworks 3.2 engine this gave an XCorr score of 2.05
(scores 1.5 are significant). An abundant ion at m/z
1374.58 confirmed the 98-Da neutral loss from the pre-
dicted [M  H] precursor ion at m/z 1472.60. The loss of
64 Da from the molecular ion also characterized the
presence of methionine sulfoxide. Further fragmentation
was indicated by the presence of the y8, y8P, and b10P
ions. The fragment ion in the MS/MS spectrum corre-
sponding to the 98-Da neutral loss was selected for MS3
Figure 4. vMALDI-MS/MS and MS3 identificat
(residues 109–120) from chymotrypsin-digested e
ion atm/z 1472.60 showing a characteristic loss of 98
confirming the conversion of phospho-Ser-118 toanalysis (Figure 4b) and Sequest gave an XCorr score of2.53. This spectrum revealed a characteristic set of se-
quence ions (y6,7,8, b9,11), the internal ion PPPQL28 and
again the loss of 64 Da. The sequence ions confirmed the
phosphorylation site as Ser-118, now converted to dehy-
dro-alanine (shown as dS), which validated this technique
for phosphopeptide identification in ER. It is noteworthy
that this peptide gave almost no signal by ESI-MS, so in
this case the use of MALDI was essential, whereas the
reverse was true for the Ser-167-phosphopeptide.
Detection of a Novel ER Phosphorylation Site
by Neutral Loss Scanning
Despite earlier studies suggesting that Ser-154 might
f phosphorylated peptide M*LLHPPPQLpS118PF
enous ER. (a) MS/MS of the putative precursor
(b) MS3 of the neutral loss fragment atm/z 1374.58,
ro-alanine.ion o
ndog
Da.be a phosphorylation site, neither the ESI-MS/MS
) wa
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cells that had not been treated with estradiol or EGF
showed peaks that could correspond to this species,
even though vMALDI-MS showed a significant peak
for an unphosphorylated peptide containing Ser-154,
EAGPPAFYRPNS154DNRR (m/z 1847.0). Previous
studies using a vMALDI-LTQ quadrupole linear ion
trap had demonstrated the power of applying a
hypothesis-driven multiple-stage MS approach for the
detection of novel phosphorylation sites on huntingtin
Figure 5. vMALDI-MS/MS, MS3 and MS4
EAGPPAFYRPNpS154DNRR (residues 143–158)
ion [M  H] at m/z 1927.0 selected for MS/MS
loss of 98 Da. (b) MS3 spectrum of m/z 182
dehydro-alanine. The c11 fragment ion (1217.7
information see inset). (c) MS/MS of the un
EAGPPAFYRPNSDNRR. The c11 ion (1217.7 m/zprotein previously undetected by ESI (Q-STAR) [31].We used a modified version of this same approach (as
used in Figure 4) to interrogate the peptides from
trypsin digests of ER isolated from E2-treated MCF-7
cells to search for previously undetected serine phos-
phorylation sites. Applying this neutral loss scanning
MS approach to interrogate all MCF-7–derived ER
tryptic peptides observed with unmodified serine resi-
dues, phosphorylation on ER Ser-154 was identified,
as shown by the spectra illustrated in Figure 5. Figure
5a shows the vMALDI-MS/MS spectrum of the ER
tification of phosphorylated tryptic peptide
MCF-7 cells treated with E2. (a) The precursor
ysis. P represents loss of phosphoric acid, i.e.,
[MH98] confirming that Ser-154 is now
was fragmented (MS4; for additional sequence
ified peptide at m/z 1847.0 corresponding to
s further fragmented (MS3; see inset).iden
from
anal
9.0
m/z)
modpeptide EAGPPAFYRPNpS154DNRR obtained from E2-
rypsi
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(0.78, below the level of significance). However, an
abundant ion at m/z 1829.1 confirmed the 98-Da neutral
loss from the [MH] precursor ion atm/z 1927.0 and
further fragmentation was indicated by c11 and b11 ions.
The 98-Da neutral loss fragment from the MS/MS
spectrum was selected for MS3 analysis (Figure 5b) and
this spectrum gave an excellent Sequest XCorr (2.47);
this spectrum also revealed an interesting set of se-
quence ions (c11, b11, b11H2O, b15, b11H2O,
b15H2O). The c11 fragment ion (1217.7m/z) was further
fragmented (MS4, inset Figure 5b) revealing the se-
quence ions (b7 and b9, y8NH3, y10) providing further
evidence that the phosphorylation site was the serine
154 residue. It is also noteworthy that the ions at 1200.5
and 1182.3 in the MS4 spectrum mimic exactly the b11
and b11H2O ions in the MS
3 spectrum.
Due to the unique fragmentation and production of
the relatively unusual c ions, further confirmation of
this interpretation was sought. MS/MS analysis of the
unmodified peptide precursor ion (m/z 1847.0; Figure
5c) gave a high XCorr score (2.78) and revealed a set of
sequence ions (c11,12, b11,13,14,15, b11H2O, b15NH3,
b15H2O) analogous to the fragmentation of the corre-
sponding neutral loss-derived dehydro-alanine-con-
taining peptide (as shown in Figure 5b, MS3 of m/z
1829.0), resulting from its phosphorylated precursor.
For the non-phosphorylated peptide at m/z 1847.0,
further fragmentation of the c11 ion (MS
3 of m/z 1217.7;
inset Figure 5c) revealed the sequence ions (b7 and b9,
y8NH3, y10) and an additional internal fragment ion
PPAFYR-NH3; thus the fragmentation was almost iden-
tical to that of the corresponding neutral loss derived
dehydro-alanine-containing peptide (inset Figure 5b;
MS4 of m/z 1217.7) derived from its phosphorylated
precursor. Table 1 summarizes the tandem mass spec-
trometry data observed for peptides containing phos-
phorylated serine residues 118, 154 or 167 and the
corresponding peptides for which these residues are not
phosphorylated. In each case M (obs) is the molecular
mass of the neutral peptide after subtraction of the
mass(es) of the attached proton(s) and M is the differ-
ence between the measured mass and that calculated
from the known atomic composition of the peptide.
Table 1. Phospho-serine peptides and corresponding unmodifie
M (obs) M (Da) Proteolytic peptides
1751.63 –0.07 LApS167TNDKGS(ox)MA(ox)MESAK T
1671.80 0.06 LAS167TNDKGS(ox)MA(ox)MESAK T
1472.60 –0.10 (ox)MLLHPPPQLpS118PF C
1392.60 –0.13 (ox)MLLHPPPQLS118PF C
1926.30 0.44 EAGPPAFYRPNpS154DNRR T
1846.00 0.11 EAGPPAFYRPNS154DNRR TMascot scores and retention times are presented onlyfor peptides monitored by HPLC-MS/MS, whereas
XCorr values are presented for peptides monitored by
vMALDI-MSn, where n was either 2 (MS/MS) or 3
(MS/MS/MS) (Table 1).
Relative Quantitation by SRM of Ser-154
Phosphorylation Induction
To assess the degree of E2- or EGF-induced ER Ser-154
phosphorylation relative to unstimulated ER from
MCF-7 cells, the ability of the vMALDI-LTQ to carry
out selected reaction monitoring (SRM) was used. This
enables the measurement of the presence and intensity
of a specific predetermined fragment ion after CID. The
MALDI mode was selected rather than LC-ESI because
it allowed peptide fragments to be monitored over a
longer period of time, whereas the LC-MS/MS experi-
ments with the Q-STAR gave only transitory signals
that were not conducive to collecting multiple measure-
ments. Given that the c11 ion was common to both
phosphorylated and unmodified peptides wewere able to
normalize for variability in total peptide levels observed
between the different samples. This ion was preferable to
the b11 ion because there was overlap between b11 and the
c11NH3 ion. An SRM method was developed that com-
pared the intensity of the c11 fragment ion (1217.6 m/z)
from the phosphorylated peptide containing ER residues
143–158 (EAGPPAFYRPNpSDNRR) with that of the same
c11 fragment ion from the corresponding unmodified ER
peptide. The data obtained from multiple biological
replicate experiments shown in Figure 6a revealed
that E2 induced a 6-fold increase in ER phosphory-
lation at Ser-154 relative to untreated control,
whereas EGF induced a weaker intracellular response
with 2.5-fold induction in ER Ser-154 phosphoryla-
tion over untreated control.
Although this report illustrates the analytical power
of modern MS approaches to discover previously un-
detected PTMs in such low abundance and clinically
relevant endogenous proteins like ER, it is also impor-
tant to note the contribution made by using different
MS instrument platforms in the identification and quan-
tification of specific ER PTMs like phospho-Ser-167
ine peptides detected
tease P-site
Mascot score
(ESI-MS/MS)
XCorr value
vMALDI-
MSn) LC tret
n Ser-167 50 — 13.5 min
n — 61 — 12.9 min
trypsin Ser-118 — 2.05 (MS2), —
2.53 (MS3)
trypsin — — 2.61 (MS2) —
n Ser-154 — 0.78 (MS2), —
2.47 (MS3)
n — 29 2.78 (MS2) 16.5 mind ser
Pro
rypsi
rypsi
hymo
hymo
rypsiand phospho-Ser-154. In particular, it is still not fully
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Ser-167 peptide (Figure 3), whereas MALDI preferentially
ionized the phospho-Ser-118 and phospho-Ser-154 pep-
tides (Figures 4 and 5) from the same ER digests,
underscoring the benefits of using different MS platforms
to achieve full protein coverage and phospho-peptide
detection. Likewise, vMALDI-LTQ provided an advan-
tage over the Q-STAR because we used its SRMmode to
quantitate relative phospho-peptide levels, allowing us
to measure differential induction of phospho-Ser-154
following E2 and EGF stimulation of MCF-7 cells. The
complementary application of different MS platforms
as demonstrated in this study also serves to emphasize
further advantages that may be gained by applying
emerging MS innovations such as electron-transfer dis-
Figure 6. Relative quantitation of phospho-Ser-154 levels by MS
and immunoblotting. (a) vMALDI-LTQ in SRM mode demon-
strates levels of Ser-154 phosphorylation after E2 (10 nM) or EGF
(50 ng/mL) treatment relative to their respective controls. (b)
Western analysis of total and phosphorylated ER at Ser-154
following immunoprecipitation from MCF-7 cells treated with E2
(10 nM), EGF (50 ng/mL), or appropriate control.sociation (ETD) fragmentation along with our presentMS approaches. The use of ETD has recently been
suggested to be superior to CID for identification of
phospho-peptides, although the two methods could be
effectively combined in alternating ETD and CID
modes for a truly comprehensive analysis of phospho-
peptides [41].
Antibody Specific to ER Phospho-Ser-154
Confirms MS Findings
Informed by the MS detection of phospho-Ser-154, a
rabbit polyclonal antibody specific to ER phospho-Ser-
154 was produced and affinity purified as described
earlier under the Experimental section. As shown in
Figure 6b, Western analysis with this ER phospho-Ser-
154 antibody performed on the same immunopurified
ER material used for MS analysis (Figure 2a) demon-
strated that E2 and EGF induced phosphorylation of
Ser-154 consistent with levels determined by MS anal-
ysis. With regard to E2-induced phosphorylation of
Ser-154, it is also interesting to note that its nearly 6-fold
induction is quantitatively similar to the E2-induced
Ser-167 phosphorylation response (Figure 2a).
A competition experiment confirmed the specificity
of the antibody to ER phosphorylated at serine-154.
The phosphopeptide used to produce the antibody was
mixed with the phospho-Ser-154 antibody at a 1000:1
ratio in the TBS-Tween/milk solution. A blot containing
multiple samples of ER immunoprecipitated from con-
trol and E2-treated MCF-7 cells was then incubated in
the peptide/antibody mix and compared to a repeat
blot that was incubated in phospho-Ser-154 antibody
alone. The competing peptide completely prevented
binding of the antibody to ER, as was shown by the
lack of signal from the 66-kDa region for all samples
incubated in the peptide/antibody mix (data not
shown).
The AF1 and AF2 domains of ER (Figure 1), both
serving to mediate gene induction by ER, do so by
different mechanisms, with AF2 activation brought
about by ligand-dependent steric recruitment of cofac-
tors to the C-terminal domain, whereas AF1 activation
and cofactor recruitment are mediated by induction of
an undefined constellation of different serine phosphor-
ylation sites within the N-terminal domain of ER [4–6,
42, 43]. With the present MS analysis establishing
Ser-154 as a phosphorylated target upon both ligand-
dependent (E2) and ligand-independent (EGF) ER
activation, 6 of 14 NTD serine residues are now known
to be subject to endogenous phosphorylation and may
thereby be considered potential regulators of AF1 func-
tion. Furthermore, our MS analyses also indicate that
Ser-10, 46, 47, 137, 173, and 178 are not subject to
endogenous phosphorylation, as determined by our
experimental conditions and within current instrumen-
tation and detection limits. Studies using other pro-
teases to improve coverage and interrogate peptides
containing the remaining serine residues within the
739J Am Soc Mass Spectrom 2008, 19, 729–740 ESTROGEN RECEPTOR NTD PHOSPHORYLATIONER-NTD are currently under way. Given such impor-
tant clinical issues as endocrine resistance, thought to be
mediated by ligand-independent NTD phosphorylation
[2, 8, 11–21], developing a complete catalogue of endog-
enous ER PTMs, now feasible using modern MS
approaches, would seem to be an important and achiev-
able endeavor.
Although the functional consequences of Ser-154
phosphorylation remain to be explored, it is interesting
to note that Scansite (scansite.mit.edu), a kinase motif
search engine, classified Ser-154, like Ser-167, as embed-
ded in a phosphorylation motif similar to that targeted
by the growth factor activated serine/threonine kinase,
AKT. Since EGF treatment of MCF-7 cells induced
substantial phospho-Ser-167 levels along with a modest
increase in endogenous phospho-Ser-154 levels, recent
reports implicating AKT-stimulated phosphorylation of
Ser-167 in association with tamoxifen resistance now
raise an interesting question about the possible clinical
relevance of phospho-Ser-154 induction in ER-positive
breast cancers, alone or in concert with phospho-Ser-
167 induction [44–46]. Such mechanistic and clinical
questions can now be more readily addressed with the
availability of our ER phospho-Ser-154–specific anti-
body, developed as a result of the MS analytical ap-
proach and findings described here.
Conclusion
Activated ER plays a critical role in the development
of most human breast cancers while also serving as the
molecular target for life saving endocrine therapies [4,
6, 47]. Many aspects of ER transcriptional activation
are modulated by phosphorylation of key serine resi-
dues within its NTD as a result of either ligand-
dependent or -independent influences [2, 7]. Initial
studies examining phosphorylation within the ER-
NTD relied on ER overexpressed in metabolically
labeled mammalian (COS) and insect (Sf9) cells [26, 27,
48]. Although these studies successfully identified sev-
eral serine residues within the NTD targeted for phos-
phorylation, including the identification of Ser-118 as a
key target residue, technical limitations left other phos-
phorylated resides contested or unidentified [26, 27, 48].
MS analysis, with its great advances in precision and
sensitivity, now plays an increasingly important role in
the detection of in vivo phosphorylated protein resi-
dues [49]. In the present study endogenous ER, immu-
nocaptured and purified from MCF-7 human breast
cancer cells shortly after either ligand-dependent or
-independent ER activating stimulation, was analyzed
by MS using two complementary platforms, ESI-
MS/MS and vMALDI-MSn, allowing for the detection
of known ER-NTD phosphorylation sites, Ser-118 and
Ser-167, as well as identification and induction of a
previously unrecognized NTD phosphorylation site,
phospho-Ser-154. MS analysis demonstrated that en-
dogenous phospho-Ser-154 induction occurs more so
in response to E2 (6-fold) than to EGF (2.5-fold)stimulation; and the presence and relative levels of
these induction responses were confirmed using a
custom-produced polyclonal antibody specific for
ER phospho-Ser-154.
This present report describes modifications in the
N-terminal domain of ER, a region that can be moni-
tored using chymotrypsin digestion. A future study in
preparation will address the issue of overall sequence
coverage using several different enzymes and will
attempt a comprehensive analysis of all the posttrans-
lational modifications of this protein (Astriku, Britton et
al., in preparation). For the current work there is no
formal measure of sensitivity but, as described in the
text, all measurements were carried out on endogenous
protein extracted from a human breast cancer cell line in
the low picomole range. The site occupancy for phos-
phorylation is typically low, so the techniques used
here can be considered very sensitive. Thus, the protein
isolation and MS strategies described here can facilitate
discovery of novel phosphorylation sites within low-
abundance, clinically important cancer targets like ER,
and may thereby contribute to our understanding of the
role of phosphorylation in the development of breast
cancer.
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